SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
-------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 6, 1999
------------------------
VERSAILLES CAPITAL CORPORATION
- -------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Colorado 0-22865 84-1044910
- -------------------------------------------------------------------------
(State or Other Jurisdiction (Commission File (IRS Employer
of Incorporation) Number) Identification No.)
21550 Oxnard Street, Suite 830, Woodland Hills, California 91367
- -------------------------------------------------------------------------
(Address of Principal Executive Offices) Zip Code
Registrant's telephone number, including area code: (818) 676-0404
-------------------
- -------------------------------------------------------------------------
(Former Name or Former Address, if Changed since Last Report)
<PAGE>
Item 5. Other Events.
On August 6, 1999, the Registrant issued the following press release
relating to the results of its annual meeting of shareholders held on
August 6, 1999:
"FOR IMMEDIATE RELEASE
FRIDAY, AUGUST 6, 1999
VERSAILLES CAPITAL CORP.'S SHAREHOLDERS
APPROVE ALL PROPOSALS AT ANNUAL MEETING
NAME CHANGE TO AMERIMMUNE PHARMACEUTICALS, INC.,
NEW TICKER SYMBOL TO TAKE EFFECT TUESDAY, AUG. 10, 1999
Versailles Capital Corp., a Colorado corporation (OTC BB: VSCC), Friday
announced that its shareholders, at the company's annual meeting,
overwhelmingly approved all four of management's proposals, including
adoption of an amendment to the company's articles of incorporation to
change the name of the company to Amerimmune Pharmaceuticals, Inc. from
Versailles Capital Corp.
The name change is effective at the start of trading on Tuesday, August 10,
1999, at which time the company's shares will begin trading under the
trading symbol AMUN. The company's shares will continue to be traded on
the OTC Bulletin Board.
Addressing the company's shareholders, the company's president and chief
executive officer, Michael A. Davis, M.D., Sc.D., stated, 'The name change
does not signify that the company is altering its focus. Rather, we
believe that the current name has very little goodwill associated with it
and the new name will be more representative of the company's plans.'
Shareholders also approved: 1) the election of six directors to serve until
the next annual meeting of shareholders and until their successors are duly
elected and qualify; 2) approval of the Versailles Capital Corp. 1998
omnibus stock incentive plan, as amended; and 3) ratification of the
selection of Ernst & Young LLP as the company's independent auditors for
the fiscal year ending March 31, 2000.
Elected to the board of directors were Daniel L. Azarnoff, M.D.; Roy S.
Azarnoff; Kimberlie L. Cerrone; Michael A. Davis, M.D.; O.B. Parrish; and
Lois Rezler. All are incumbent directors.
Founded in 1999, the company is engaged in pharmaceutical research and
development, with the primary purpose of developing Cytolin(R), a drug
designed to protect the immune
2
<PAGE>
system, especially in patients suffering from Human Immunodeficiency Virus
(HIV).
The company believes that Cytolin(R) is an important drug for the growing
number of patients who have not been receiving treatment, for those who are
on multidrug therapy, and for those who have become resistant to drugs
currently used to treat the HIV/AIDS virus.
Statements made in this news release that are not historical facts, such as
anticipated results of clinical trials, may constitute 'forward-looking
statements,' which are made pursuant to the safe-harbor provisions in the
federal securities laws. Forward-looking statements are subject to risks,
uncertainties and other factors beyond the control of the company that
could cause actual results to differ materially from those set forth in,
contemplated by or underlying the forward-looking statements. Factors that
could cause actual results to differ materially from the company's
expectations are detailed in the company's filings with the Securities and
Exchange Commission, including the company's annual report on Form 10-KSB.
The company disclaims any obligation to revise any forward-looking
statements to reflect events or circumstances after the date of such
statement or to reflect the occurrence of anticipated or unanticipated events."
3
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
VERSAILLES CAPITAL CORPORATION
(Registrant)
By: /s/ Wellington A. Ewen
--------------------------------
Wellington A. Ewen, C.P.A., M.B.A.
Chief Financial Officer
Date: August 10, 1999
4
